Updates are available Correction dated 2020-12-09

Article History

Received: 30 June 2020

Revised: 27 August 2020

Accepted: 10 September 2020

First Online: 13 October 2020

Change Date: 26 February 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s00467-020-04874-z

Compliance with ethical standards

:

: Kazuki Tanaka has received research support and consultation fees from Alexion Pharma GK. Brigitte Adams has no competing interests to declare. Alvaro Madrid Aris has no competing interests to declare. Naoya Fujita has no competing interests to declare. Masayo Ogawa is an employee and shareholder of Alexion Pharmaceuticals Inc. Stephan Ortiz is an employee and shareholder of Alexion Pharmaceuticals Inc. Marc Vallee is a shareholder of Alexion Pharmaceuticals Inc. Larry A. Greenbaum has received research support and consultation fees from Alexion Pharmaceuticals. He also serves on the scientific advisory board of the International aHUS Registry, sponsored by Alexion Pharmaceuticals.

: This trial was conducted in accordance with (1) the consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, (2) the ICH GCP Guideline [E6], (3) the ICH Clinical Trials of Medicinal Products in the Pediatric Population [E11], and (4) applicable national and local laws and regulations.

: A written informed consent was obtained from all individual participants or legal guardians, as applicable.

: All authors consent to the publication of this manuscript.

: Not applicable.